Skip to content
A895Assembly2023-2024 SessionSame asS3518

Require Drug Deal Disclosure

Official title

“Enacts the manufacturer disclosure and transparency act”

Status
In Assembly Committee
Consumer Affairs And Protection
Impact
7/10
Significant
Passage
0%

Bill progress

Step 2 of 7

In committee · Consumer Affairs And Protection

What's happening

This bill requires drug manufacturers to disclose agreements that delay generic drugs to the attorney general, with penalties for noncompliance.

Why it matters

  1. Increases transparency. by requiring drugmakers to publicly disclose when they make deals that delay cheaper generic drugs, allowing patients, providers, and state agencies to track which drugs are being withheld from the market and by whom.

  2. Facilitates oversight and accountability. by mandating that the Attorney General, Medicaid plans, health carriers, and pharmacy benefit managers receive timely information about such agreements, potentially enabling earlier investigation or intervention.

  3. Imposes financial penalties. on manufacturers who fail to report these deals, creating a deterrent against nondisclosure and encouraging compliance.

  4. Empowers the public and policymakers. by making searchable data on delayed generics available online, potentially influencing future legislation, litigation, or consumer advocacy efforts to reduce drug prices.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Require Drug Deal Disclosure

Plain English, a few words. Used as the page title.

Sponsors

History

  1. Referred to consumer affairs and protection
  2. Referred to consumer affairs and protection

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

S3518Senate

Expose Delayed Generic Drugs

In Assembly Committee · Consumer Affairs And Protection · Sponsor Nathalia Fernandez

Impact 7 · Significant0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

895

2023-2024 Regular Sessions

IN ASSEMBLY

January 11, 2023

Introduced by M. of A. GALLAGHER, STIRPE, DICKENS, FORREST, MAMDANI -read once and referred to the Committee on Consumer Affairs and Protection

AN ACT to amend the general business law, in relation to requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic drugs

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. This act shall be known and may be cited as the "manufacturer disclosure and transparency act".

§ 2. The general business law is amended by adding a new section 396- rrr to read as follows:

§ 396-rrr. Delay of introduction of generic medications. 1. (a) Each pharmaceutical manufacturer doing business in this state that manufactures a brand name prescription drug and enters into an arrangement, through agreement or otherwise, with another pharmaceutical manufacturer that has the purpose or effect of delaying or preventing such other manufacturer from introducing a generic substitute for such drug into the marketplace shall, not later than thirty days after entering into such arrangement, send notice to the attorney general, in a form and manner prescribed by the attorney general, disclosing the name of such drug, the wholesale price, the disease such drug is commonly prescribed to treat, the manufacturer of such drug, the name of the generic manufacturer, and the length of the delay.

(b) The attorney general shall, no later than thirty days after receiving a notice pursuant to paragraph (a) of this subdivision, share the information with the drug utilization review board established under section three hundred sixty-nine-bb of the social services law, all medicaid managed care plans, health carriers and pharmacy benefits

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD00235-01-3

managers doing business in the state in a format and manner prescribed by the attorney general.

2. The office of the attorney general shall post on its website all the notices required pursuant to paragraph (a) of subdivision one of this section in a format and manner developed by the attorney general that is searchable by drug, cost, disease, and manufacturer both for the brand and generic drug for public review.

3. For a violation by a manufacturer of a brand name drug who knowingly or negligently fails to notify the attorney general as required in paragraph (a) of subdivision one of this section, the attorney general shall fine such manufacturer no less than five thousand dollars for the first violation for each day such manufacturer fails to properly notify the attorney general pursuant to the requirements of this section and no less than ten thousand dollars for each violation thereafter for each day such manufacturer fails to properly notify the attorney general pursuant to the requirements of this section.

4. The attorney general is authorized to promulgate rules and regulations necessary for the implementation of this section.

§ 3. This act shall take effect on the one hundred eightieth day after it shall have become a law.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.